Trials / Completed
CompletedNCT04957160
Cabozantinib Post First-line Immuno-oncology Checkpoint Inhibitor Containing Combination
A Multicentre, Retrospective, Non-interventional Review of Electronic Prescribing Records of Any Second-line (2L) Patients and Chart Notes of 2L Cabozantinib Patients, Investigating the Treatment Sequence Pathway Following a First-line, Immuno-oncology Checkpoint Inhibitor (1L IO) Containing Combination Therapy in Patients With Advanced Renal Cell Carcinoma (aRCC) (CARINA)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 281 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will collect real-world data for the new treatment pathways for all patients with Advanced Renal Cell Carcinoma (ARCC) who were treated with a 1L IO (first-line, Immuno-Oncology checkpoint inhibitor) combination therapy and progressed to a 2L treatment with particular focus to understanding where cabozantinib is prescribed after 1L IO containing combination therapy.
Conditions
Timeline
- Start date
- 2021-09-09
- Primary completion
- 2022-06-15
- Completion
- 2022-06-15
- First posted
- 2021-07-12
- Last updated
- 2024-12-17
Locations
9 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04957160. Inclusion in this directory is not an endorsement.